Trials / Terminated
TerminatedNCT00531271
ABI-008 Trial in Patients With Metastatic Breast Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Metastatic Breast Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 85 (estimated)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule to patients with metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-008 (nab-docetaxel) | ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-09-18
- Last updated
- 2019-11-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00531271. Inclusion in this directory is not an endorsement.